S&T BioMed 將參展 IFHNOS 2026，展示 EarlyFound® 口腔癌早期檢測平台
S&T BioMed 將參加於澳洲布里斯本舉辦的 IFHNOS 2026（The 8th World Congress of the International Federation of Head and Neck Oncologic Societies），與全球頭頸腫瘤領域醫師、專家及合作夥伴交流，展示 EarlyFound® Oral Cancer Detection Platform。
目前 EarlyFound® ELISA 已取得 歐盟 IVDD、泰國、越南、澳洲、新加坡、香港、馬來西亞及菲律賓上市許可；EarlyFound® Rapid Test 已取得 歐盟 IVDD、泰國、越南、澳洲及新加坡上市許可。
我們期待透過 IFHNOS 2026 與國際臨床及產業夥伴建立更多合作機會，共同推動口腔癌早期診斷與精準醫療的發展。
S&T Biomed to Exhibit at IFHNOS 2026
S&T Biomed will participate in IFHNOS 2026, the 8th World Congress of the International Federation of Head and Neck Oncologic Societies, in Brisbane, Australia, to showcase the EarlyFound® Oral Cancer Detection Platform and connect with leading clinicians and partners worldwide.
EarlyFound® ELISA is approved in the EU (IVDD), Thailand, Vietnam, Australia, Singapore, Hong Kong, Malaysia, and the Philippines.
EarlyFound® Rapid Test is approved in the EU (IVDD), Thailand, Vietnam, Australia, and Singapore.
We look forward to building new international collaborations and advancing early detection for oral cancer.
